Treatment of rheumatoid arthritis in the third millennium

References

• Cush JJ, Lipsky PE. The immunopathogenesis of rheumatoid arthritis: the role of cytokines in chronic inflammation. Clin Aspects Autoimmun 1987;1:2–12.
   Google Scholar
• Cush JJ, Lipsky PE. Cellular basis for rheumatoid inflamma-tion. Clin Orthop 1991;265:9–22.
   Google Scholar
• Harris ED. Rheumatoid arthritis: Pathophysiology and implications for treatment. N Engl J Med 1990;322:1277–89.
   PubMed Web of Science ®Google Scholar
• Kvalvik AG, Jones MA, Symmons DPM. Mortality in a cohort of Norwegian patients with rheumatoid arthritis fol-lowed from 1977 to 1992. Scand J Rheumatol 2000;29: 29–37.
   Google Scholar
• Simonsson M, Bergman S, Jacobsson LTH, Petersson IF, Svensson B. The prevalence of rheumatoid arthritis in Sweden. Scand J Rheumatol 1999;28:340–3.
   Google Scholar
• Kvien TK, Glennas A, Knudsrod OG, Smestad LM, Mowinckel P, Barre O. The prevalence and severity of rheum-atoid arthritis in Oslo. Scand J Rheumatol 1997;26:412–8.
   PubMed Web of Science ®Google Scholar
• Kalden JR, Breedveld FC, Burkhardt H, Burmester GR. Immunological treatment of autoimmune diseases. Adv Immunol 1998;68:333–418.
   PubMed Web of Science ®Google Scholar
• Schulze-Koops H, Burkhardt H, Kalden JR. What we have learned from trials of immunomodulatory agents in RA: Future directions. Drugs Today 1999;35:327–51.
   Google Scholar
• Schulze-Koops H, Lipsky PE. Anti-CD4 monoclonal antibody therapy in human autoimmune diseases, In: Fathman CG, ed. Biologic and gene therapy of autoimmune disease. Basel: Karger Press Ltd., 2000:24–49.
   Google Scholar
• Schulze-Koops H, Davis LS, Haverty TP, Wacholtz MC, Lipsky PE. Reduction of Thl cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4. J Rheumatol 1998;25: 2065–76.
   Google Scholar
• Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996;14:1–27.
   Google Scholar
• Brocke S, Gijbels K, Allegretta M, Ferber I, Piercy C, Blankenstein T, et al. Treatment of experimental encephalomy-elitis with a peptide analogue of myelin basic protein. Nature 1996;379:343–6.
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumat-oid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932–9.
   PubMed Web of Science ®Google Scholar
• Williams RO, Mason LJ, Feldmann M, Maini RN. Synergy between anti-CD4 and anti-tumor necrosis factor in the ameli-oration of established collagen-induced arthritis. Proc Natl Acad Sci USA 1994;91:2762–6.
   PubMed Web of Science ®Google Scholar
• Isaacs JD, Morgan AW, Strand V. Combination biologic therapy. Clin Exp Rheumatol 1999;17:5121–4.
   Google Scholar
• Morgan AW, Hale G, Waldmann H, Emery P, Isaacs JD. Prolonged combination therapy of RA using CD4 and TNFce blockade - a pilot study. Arthritis Rheum 1998;41: 5551.
   Google Scholar
• Adorini L, Guery JC, Trembleau S. Manipulation of the Thl/Th2 cell balance: an approach to treat human autoimmune diseases? Autoimmunity 1996;23: 53–68.
   Google Scholar
• Saoudi A, Kuhn J, Huygen K, de Kozak Y, Velu T, Goldman M, et al. TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. Eur J Immunol 1993;23: 3096–103.
   Google Scholar
• Fowell D, Mason D. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4 + T cell subset that inhibits this autoimmune potential. J Exp Med 1993;177:627–36.
   Google Scholar
• Van der Veen RC, Stohlman SA. Encephalitogenic Th1 cells are inhibited by Th2 cells with related peptide specificity: relative roles of interleukin (IL)-4 and IL-10. J Neuroimmunol 1993;48:213–20.
   PubMed Web of Science ®Google Scholar
• Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS. Elevated Thl- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis: Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol 1995;155: 5029–37.
   Google Scholar
• Wong WM, Vakis SA, Ayre KR, Ellwood CN, Howell WM, Tutt AL, et al. Rheumatoid arthritis T cells produce Th 1 cytokines in response to stimulation with a novel trispecific antibody directed against CD2, CD3, and CD28. Scand J Rheumatol 2000;29:282–7.
   PubMed Web of Science ®Google Scholar
• Rocken M, Racke M, Shevach EM. IL-4-induced immune deviation as antigen-specific therapy for inflammatory auto-immune disease. Immunol Today 1996;17: 225–31.
   Google Scholar
• Skapenko A, Wendler J, Lipsky PE, Kalden JR, Schulze-Koops H. Altered memory T cell differentiation in patients with early rheumatoid arthritis. J Immunol 1999;163:491–9.
   Google Scholar
• Lipsky PE, Davis LS, Cush JJ, Oppenheimer-Marks N. The role of cytokines in the pathogenesis of rheumatoid arthritis. Springer Semin Immunopathol 1989;11:123–62.
   PubMed Web of Science ®Google Scholar
• Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105–10.
   PubMed Web of Science ®Google Scholar
• Rankin EC, Choy EH, Kassimos D, Kingsley GH, Sopwith AM, Isenberg DA, et al. The therapeutic effects of an engine-ered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334–42.
   PubMedGoogle Scholar
• Kavanaugh A, St. Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha mono-clonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol 2000;27:841–50.
   PubMed Web of Science ®Google Scholar
• Sander O, Rau R, van Riel P, van der Putte L, Hasler F, Baudin M, et al. Neutralization of TNF by lenercept (TNFR55-IgG1, Ro 45–2081) in patients with rheumatoid arthritis treated for three months: Results of a European phase II trial. Arthritis Rheum 1996;39: 5242.
   Google Scholar
• Maini RN, Taylor PC. Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med 2000;51:207–29.
   PubMed Web of Science ®Google Scholar
• Charles PJ, Elliott MJ, Feldmann M. Development of anti-ds DNA antibodies in patients with rheumatoid arthritis treated with a chimeric monoclonal antibody to TNF alpha. EULAR J 1995;24:B114.
   Google Scholar
• Benson JM, Stuckman SS, Cox KL, Wardrop RM, Gienapp IE, Cross AH, et al. Oral administration of myelin basic protein is superior to myelin in suppressing established relaps-ing experimental autoimmune encephalomyelitis. J Immunol 1999;162:6247–54.
   PubMed Web of Science ®Google Scholar
• Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1994;12:809–37.
   Google Scholar
• Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, Haller DA, Weiner HL. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993;261:1727–30.
   PubMed Web of Science ®Google Scholar
• Krause I, Blank M, Shoenfeld Y. Immunomodulation of experimental autoimmune diseases via oral tolerance. Crit Rev Immunol 2000;20:1–16.
   Google Scholar
• Barnett ML, Kremer JM, St Clair EW, Clegg DO, Furst D, Weisman M, et al. Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, pla-cebo-controlled trial. Arthritis Rheum 1998;41:290–7.
   PubMed Web of Science ®Google Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309–19.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95:3597–602.
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165–76.
   PubMed Web of Science ®Google Scholar
• Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304–9.
   PubMed Web of Science ®Google Scholar
• Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250–8.
   PubMed Web of Science ®Google Scholar
• Davis MW, Feige U, Bendele AM, Martin SW, Edwards CK. Treatment of rheumatoid arthritis with PEGylated recombin-ant human soluble tumour necrosis factor receptor type I: a clinical update. Ann Rheum Dis 2000;59 Suppl 1:141–3.
   Google Scholar
• Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739–46.
   PubMed Web of Science ®Google Scholar
• Kumar S, Votta BJ, Rieman DJ, Badger AM, Gowen M, Lee JC. IL-1- and TNF-induced bone resorption is mediated by p38 mitogen activated protein kinase. J Cell Physiol 2001;187:294–303.
   PubMedGoogle Scholar
• Skapenko A, Lipsky PE, Kraetsch HG, Kalden JR, Schulze-Koops H. Antigen-independent Th2 cell differentiation by stimulation of CD28: regulation via IL-4 gene expression and mitogen-activated protein kinase activation. J Immunol 2001; 166:4283–92.
   Google Scholar